The Safety and Efficacy of Irreversible Electroporation for Large Hepatocellular Carcinoma

Jianying Zeng, MD1,2, Guifeng Liu, MD1, Zhong-hai Li, MD1, Yi Yang, MD1, Gang Fang, MD1, Rong-rong Li, MD1, Ke-cheng Xu, MD1, and Lizhi Niu, MD, PhD1

Abstract
This study aimed to investigate the safety and effectiveness of irreversible electroporation ablation for unresectable large liver cancer. Fourteen patients were enrolled: 8 with large hepatocellular carcinoma (tumor diameter: 5.1-11.5 cm) and 6 with medium hepatocellular carcinoma (tumor diameter: 3.0-4.1 cm). All patients received percutaneous irreversible electroporation ablation. Ablation time and the incidence of complications were assessed by a t test. Post-irreversible electroporation and regular contrast-enhanced computed tomography scans were performed to investigate the effect of tumor size (large vs medium) on irreversible electroporation treatment efficacy; 4-table data were assessed using a Fisher exact test. The 14 patients completed irreversible electroporation ablation successfully. In the large hepatocellular carcinoma group, no major complications occurred in the perioperative period. Minor complications comprised bloating, hypokalemia, edema, low white blood cells, and blood clotting abnormalities. All complications were mild and improved after symptomatic treatment. The frequency of minor complications was not significantly different (p > .05) compared with the medium hepatocellular carcinoma group. The average follow-up time was 2.8 ± 2.1 months and complete ablation was achieved in 25% (2/8; residual = 75%). For the patients with medium hepatocellular carcinoma, the mean follow-up time was 4.3 ± 3.2 months; the rate of complete ablation was 66.6% (4/6; residual rate = 33.3%). The complete ablation rate was not statistically different between the 2 groups (p > .05). Irreversible electroporation ablation for unresectable large hepatocellular carcinoma is safe, with no major complications. Short-term efficacy is relatively good; however, long-term efficacy remains to be explored.

Keywords
hepatocellular carcinoma, irreversible electroporation, percutaneous, safety, short term

Abbreviations
CT, computed tomography; HCC, hepatocellular carcinoma; ICC, intrahepatic cholangiocellular carcinoma; IRE, Irreversible electroporation; MWA, microwave ablation; RFA, radiofrequency ablation; US, ultrasound

Introduction
Primary liver cancer is the most common malignant tumor, mainly caused by alcoholic cirrhosis, viral hepatitis, and fatty hepatitis. The incidence of primary liver cancer is 5 to 8 times higher in China than in the United States and Europe because of the increased prevalence of hepatitis B virus infection in China. Although surgery is the gold standard treatment for patients with primary liver cancer, it is suitable only for less than 20% of patients.1 Patients with unresectable tumors are often

1 Department of General Surgery, Fuda Cancer Hospital, Jinan University School of Medicine, Guangzhou, China
2 Central Laboratory, Fuda Cancer Institute, Guangzhou, China

Corresponding Author:
Lizhi Niu, MD, PhD, Fuda Cancer Hospital, Jinan University School of Medicine, Guangzhou 510665, China.
Email: 343314630@qq.com

Creative Commons CC-BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
treated with chemotherapy; however, there are some side effects and its efficacy is limited. Currently, radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation, and other minimally invasive therapies and local treatments are being used increasingly to treat liver cancer. However, RFA and MWA are not suitable for tumors larger than 5 cm, and because of the “heat sink” effect, they cannot completely ablate tumors near the great vessels.\(^3\) Using cryoablation, it is difficult to avoid the damage in large blood vessels and other important structures, and there are a series of complications caused by rupture puck. In recent years, irreversible electroporation (IRE) has been used increasingly in the clinic, providing a new choice for liver cancer. The IRE ablation uses a high-pressure pulse current that acts on the target cell membrane, resulting in unrecoverable nanoscale perforation. This leads to cell death and tumor ablation, without damaging adjacent tissue blood vessels, gall bladder, and other vital organs.\(^3\) Thus, for large hepatocellular carcinoma (HCC) and/or HCC adjacent to large vessels, IRE ablation may be a more appropriate choice. This study focused on the safety of the clinical application of IRE ablation for patients with large liver HCC whose tumors had maximum diameter greater than 5 cm.

### Materials and Methods

The clinical trial was registered with the US National Institutes of Health (ID:NCT02329106) and was approved by the regional ethics committee at Guangzhou Fuda Hospital. Each participant provided written informed consent in accordance with the Declaration of Helsinki.

We performed a prospective search for patients undergoing IRE for HCC from July 2015 to March 2016. The inclusion criteria were preoperative histopathological diagnosis of primary liver cancer, preoperative performance status score \( \leq 2, \) and not eligible for surgical resection. The exclusion criteria were: could not tolerate anesthesia through the trachea, severe coagulopathy insufficiency, severe liver and kidney function insufficiency, and cardiac pacemaker or defibrillator.

According to the inclusion and exclusion criteria, 14 patients were enrolled. According to the preoperative tumor size, the 14 cases were divided into a large HCC group (preoperative imaging determine the maximum tumor diameter greater than 5 cm)\(^5\) and a medium HCC group. The large HCC group had 8 patients (5 males and 3 females, age 24 to 65 years, mean age 50 \( \pm \) 13 years): 6 cases of HCC and 2 cases of intrahepatic cholangiocarcinoma (tumor diameter 5.1-11.5 cm, mean diameter 7.2 \( \pm \) 2.2 cm). The medium HCC group had 6 patients (all males, mean age 57 \( \pm \) 11 years): 2 cases of HCC and 4 cases of intrahepatic cholangiocarcinoma (tumor diameter 3.0-4.1 cm, mean diameter 3.5 \( \pm \) 0.5 cm). General information for all the patients is shown in Table 1.

The IRE was performed using an IRE ablation system (NanoKnife; AngioDynamics, Queensbury, New York). The main configuration included a high-voltage current generator (maximum power output of 3 kV, 50 A), an electrocardiogram (ECG) synchronization (an AccuSyneR synchronizer Device, AccuSync Medical Research Corporation, Milford, Connecticut), and two 15-cm monopolar probes. The perioperative treatment plan was based on preoperative computed tomography (CT) imaging, which decided the number and spacing of the probes. Patients were given general anesthesia and muscle relaxants. Probes were placed under ultrasound (US; IU22; Philips Medical Systems, Bothell) and CT (CT SOMATOM Definition 64 AS; Siemens Medical Solutions, Forchheim, Germany) image-guidance. The probe spacing was 1.2 to 2.5 cm, and the effective exposure probe distance was 1.5 to 2.5 cm.\(^5\) Energy was then applied at 800 to 2200 V/cm (pulse length was 90 \( \mu \)s,\(^6\) pulse repetition was 70-90). Before delivering all therapeutic pulse, a test pulse was delivered. After the test pulse proceeded smoothly, a therapeutic pulse was delivered in less than 2 minutes. All pulses were delivered in the ventricular refractory period to avoid the

### Table 1. General Information for 14 Cases of Primary Liver Hepatocellular.

| Number\(^a\) | Sex | Age (Years) | Tumor Type | Cancer Stage\(^b\) | Tumor Size (cm \( \times \) cm) | Child-Pugh | Hepatitis | AFP (IU/mL) |
|-------------|-----|-------------|------------|------------------|-------------------------------|------------|-----------|------------|
| 1           | Male| 40          | HCC        | IIIA             | 8.7 \( \times \) 3.8          | B          | B\(^+\)   | 241.8      |
| 2           | Male| 59          | HCC        | III              | 5.4 \( \times \) 3.7          | A          | –         | 3.4        |
| 3           | Male| 61          | ICC        | IIIC             | 11.5 \( \times \) 6.7         | A          | B\(^+\)   | 144.6      |
| 4           | Female| 24         | HCC        | III              | 6.7 \( \times \) 3.7          | A          | B\(^+\)   | 1967       |
| 5           | Male| 47          | HCC        | II               | 5.3 \( \times \) 4.4          | A          | B\(^+\)   | 5          |
| 6           | Male| 65          | ICC        | IIIB             | 6.8 \( \times \) 6.3          | B          | –         | 12.77      |
| 7           | Female| 45         | ICC        | III              | 5.1 \( \times \) 4.8          | A          | –         | 2.41       |
| 8           | Female| 61         | ICC        | III              | 7.8 \( \times \) 5.2          | A          | –         | 10         |
| 9           | Male| 52          | ICC        | III              | 3.2 \( \times \) 2.8          | A          | –         | 1.67       |
| 10          | Male| 50          | HCC        | IIIB             | 3.9 \( \times \) 3.5          | A          | B\(^+\)   | 14.29      |
| 11          | Male| 78          | ICC        | III              | 3 \( \times \) 3            | A          | –         | 16.82      |
| 12          | Male| 51          | ICC        | III              | 3.6 \( \times \) 2.9          | A          | –         | 2.78       |
| 13          | Male| 49          | ICC        | III              | 3 \( \times \) 3            | A          | –         | 8.56       |
| 14          | Male| 63          | HCC        | III              | 4.1 \( \times \) 2.3          | B          | –         | 13756      |

Abbreviations: AFP, alpha fetoprotein; HCC, hepatocellular carcinoma; ICC, intrahepatic cholangiocellular carcinoma.
\(^a\)All of the patients were from China.
\(^b\)Cancer stage, according to American Joint Committee on Cancer (AJCC) staging system (2002).
occurrence of arrhythmias because electrocardiogram (ECG) synchronization monitored the patients’ R wave and sent the signal to the IRE generator which released the pulse energy after a 50-μs delay. Treatment was repeated to cover the entire target if the target treatment zone was greater. After removal of the 2 needles, CT imaging was performed. The patients continued to be sedated with mechanical ventilation for 2 hours. Patients were then transferred to the intensive care unit for 24 hours. After their vital signs were stable, the patients were transferred to general wards and were provided with anti-infection treatment, drugs to protect the stomach and liver, and nutrition and other symptomatic and supportive treatments.

After the procedure, patients were followed up with contrast-enhanced CT scans at 1 to 3 months and at 3-month intervals. Complete ablation of the tumor was defined as an ablation region beyond the tumor, with clear boundaries and no evidence of arterial enhancement. Adverse events were recorded as per the unified standardized Society of Interventional Radiology grading system. The definition of a major complication is an event that leads to substantial morbidity and disability that increases the hospital stay or the morbidity. All other complications were considered minor. Common procedural side effects such as pain, fever, and transient elevation of liver enzyme levels were excluded from the evaluation.

Data were analyzed using the SPSS 13 software for statistical analysis and were represented as X ± s. To investigate the effect of tumor size (large vs medium) on IRE treatment efficacy, 4-table data were assessed using the Fisher exact test. Ablation time and the incidence of complications were assessed by a t test. P < .05 was considered statistically significant.

**Results**

Eight large liver tumors received a total of 136 cycles of IRE ablation. The procedure time was 70 to 125 min/case, with an average procedure time of 99 ± 23 min/case. The 6 medium liver tumors received a total of 33 cycles of IRE ablation. The procedure time was 45 to 75 min/case, with an average procedure time of 61 ± 10 min/case. The procedure time for medium liver tumors was significantly lower (P < .05) compared with that for large liver tumor. All patients received percutaneous ablation under US and CT guidance, and the ablation area completely covered the tumor. The parameters of IRE ablation are shown in Table 2.

**Complications**

All patients tolerated IRE well. In the large HCC group, no treatment-related bleeding or other major adverse events occurred in the perioperative period. One patient had intraoperative blood pressure up to 200/83 mm Hg (1 mm Hg = 0.133 kPa), with a suspected IRE ablation zone near the adrenal gland, which returned to normal after treatment with intravenous nicardipine (0.5 mg). Minor adverse events comprised 3 cases of hypokalemia on postoperative day 1, which was improved by oral or intravenous potassium; 1 patient had low blood pressure, low white blood cells, and platelet function abnormalities postoperatively, which were improved by intravenous infusion of dopamine and phenylephrine or the same type of plasma. There were 4 cases of abdominal distension and 2 cases of limb edema, both were mild and improved after general symptomatic treatment.

In the medium HCC group, no major adverse events occurred in the perioperative period. One patient showed intraoperative heart rate acceleration up to 140 beats/min. Minor adverse events were 3 cases of hypokalemia, 3 cases of low serum albumin, 1 case of low blood pressure, and 1 case of stomach pain. The frequency of adverse events in the medium HCC group was not significantly different (P > .05) compared to that in the large HCC group.

**Clinical Follow-Up**

In the large HCC group, the mean follow-up was 2.8 ± 2.1 months, with a median follow-up of 2.5 months. The rate of complete ablation was 25% (2/8), with a residual rate of 75%. One HCC patient, with stage II HCC, had a tumor mass of 5.3 × 4.4 cm on preoperative contrast-enhancement CT (Figure 1A and B). The intraoperative CT treatment planning system guided the 2 electrode needles into the liver tumor (Figure 1C and D). An immediate postoperative CT examination showed the multiple treatment areas of the liver tumor as shadows. A contrast-enhanced CT scan on postoperative day 7 showed that the tumor had bubble, the tumor size was 8.8 × 6.6 × 5.2 cm, the edge of this lesion was heterogeneously enhanced, and the central necrosis area showed no enhancement (Figure 1E). A postoperative contrast-enhanced CT scan at 2 months showed that the size of tumor was 4.9 × 4.3 × 4.3 cm, without evidence of enhancement, representing complete tumor ablation (Figure 1F).

In the medium HCC group, the mean follow-up was 4.3 ± 3.2 months, with a median follow-up of 4.5 months. The rate of complete ablation was 66.6% (4/6), which was not significantly different compared with the large HCC group (P > .05; Table 3), the residual rate was 33.3%.

**Discussion**

Large HCC (>5 cm) is difficult to treat surgically because of the proximity of blood vessels, the biliary tract, and vital organs;
Thus, ablation is an alternative treatment. Traditional thermal ablation has certain limitations. First, thermal ablation is only useful for lesions smaller than 3 cm; for large HCC, the complete ablation rate is 10% to 25%. Second, thermal ablation needs to reach 60°C in the target tissue to cause cell death; however, large tumors near blood vessels cannot be completely ablated and show a high recurrence rate because it is difficult to reach this temperature in the tumor due to the heat sink effect. Finally, thermal ablation damages the adjacent normal structures of the ablation zone, causing a high incidence of complications. The IRE ablation is nonthermal, with no heat sink effect, and can protect the structure of blood vessels, bile ducts, and other vital organs. Thus, IRE can ablate the tumor near the inferior vena cava, the large hepatic artery, or the portal vein.

In this study, in the 8 patients with large HCCs, the IRE procedure was well tolerated: no deaths, major complications such as bleeding, or other treatment-related adverse events occurred. Minor complications in the large HCC group were not significantly different from those in the medium HCC group. Livraghi et al. reported that the major complication rate of 2320 patients with liver tumors who received multi-center RFA was 2.2%, and the mortality was 0.3%; the main complications were bleeding and intestinal perforation. In this study, the major adverse reaction rate was 0, indicating that IRE ablation of unresectable liver cancer is safe and feasible. Dollinger reported that the major complication rate of 56 patients with 85 liver tumors who received IRE ablation was 7.1% (6/85), which showed that IRE ablation of unresectable liver tumors was safe and was consistent with our findings.

This study was the first to focus on patients with large liver tumors who received IRE ablation. In the large HCC group, the average follow-up time was 2.8 ± 2.1 months, and the complete ablation rate was 25% (2/8). In the medium HCC group, the mean follow-up time was 4.3 ± 3.2 months, and the complete ablation rate was 66.6% (4/6). The complete ablation rate in the large HCC was not significantly different (P > .05) compared with the medium HCC patients. If there was a reasonably larger sample size, a statistical difference should be observed. Cheung reported a complete ablation rate of 72% for 18 tumors at 18 months post-IRE. In comparison, our results for the complete ablation rate were unsatisfactory, mainly because of the mean tumor diameter of Cheung’s study being 2.44 ± 0.09 cm and the length of follow-up time being up to 18 months.

Table 3. Effect of Tumor Size on Outcome of IRE Ablation.

| Tumor Type                        | Complete Ablation (%) | Residual | Complete Ablation (%) | P   |
|-----------------------------------|-----------------------|----------|-----------------------|-----|
| Large hepatocellular carcinoma    | 25                    | 25       | 2                     | .277|
| Medium hepatocellular carcinoma   | 66.6                  | 66.6     | 4                     |     |

Abbreviation: IRE, irreversible electroporation.
However, Livraghi\textsuperscript{14} reported that for 46 cases of HCC (tumor diameter of 5.1-9.5 cm), the complete necrosis rate was 24\% at 5 months post-RFA, which was slightly lower than our findings. Thus, for large HCC, IRE ablation might be a better choice than RFA because of its higher safety and efficacy.

When IRE probes were inserted percutaneously into the tumor tissue, it was difficult to determine accurately the ablation region because of the metal artifacts or angle limitation, which affected the imaging monitor, so there was a certain risk of accidental injury to other organs or blood vessels. In this study, percutaneous IRE ablation used 2 probes that could divide the tumor into multiple partitions and perform the ablation many times, which greatly reduced the risk of vascular puncture and improved the safety of IRE ablation. The disadvantage was the increased ablation time: the large liver cancer ablation time was significantly longer than that for patients with medium cancer in this study ($P < .05$).

In conclusion, IRE ablation for large HCC is safe and highly effective compared with RFA and should be promoted in the clinic. However, this study focused on the safety of IRE ablation and only studied its short-term efficacy. The study had the following limitations: the small group of patients and the short follow-up time; therefore, the long-term efficacy of IRE should be studied by extending the group of patients and increasing the period of follow-up.

**Authors’ Note**
Jianying Zeng and Guifeng Liu contributed equally to this work and share first authorship.

**Acknowledgments**
The authors thank all patients who took part in this clinical research.

**Declaration of Conflicting Interests**
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by International Scientific Fund of Fuda Cancer Hospital, Guangzhou (Y2015-ZD-001).

**References**
1. Lai EC, Fan ST, Lo CM, Chu KM, Liu CL, Wong J. Hepatic resection for hepatocellular carcinoma. An audit of 343 patients. Ann Surg. 1995;221(3):291-298.
2. Livraghi T, Lazzaroni S, Meloni F. Radiofrequency thermal ablation of hepatocellular carcinoma. Eur J Ultrasound. 2001;13(2):159-166.
3. Long G, Bakos G, Shires PK, et al. Histological and finite element analysis of cell death due to irreversible electroporation. Technol Cancer Res Treat. 2014;13(6):S61-S69.
4. Goldberg SN, Grassi CJ, Cardella JF, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria. J Vasc Interv Radiol. 2009;20(7 suppl):S377-S390.
5. Appelbaum L, Ben-David E, Faroja M, Nissenbaum Y, Josna J, Goldberg SN. Irreversible electroporation ablation: creation of large-volume ablation zones in vivo porcine liver with four-electrode arrays. Radiology. 2014;270(2):416-424.
6. Ben-David E, Ahmed M, Faroja M, et al. Irreversible electroporation: treatment effect is susceptible to local environment and tissue properties. Radiology. 2013;269(3):738-747.
7. Poulou LS, Botsa E, Thanou I, Ziakas PD, Thanos L. Percutaneous microwave ablation vs radiofrequency ablation in the treatment of hepatocellular carcinoma. World J Hepatol. 2015;7(8):1054-1063.
8. Muller S, Ni Y, Jamart J, Ruers T, Marchal G, Michel L. Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Ann Surg. 2005;242(2):158-171.
9. Cannon R, Ellis S, Hayes D, Narayanan G, Martin RC II. Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. J Surg Oncol. 2013;107(5):544-549.
10. Li W, Fan Q, Ji Z, Qiu X, Li Z. The effects of irreversible electroporation (IRE) on nerves. PLoS One. 2011;6(4):e18831.
11. Livraghi T, Solbiati L, Meloni MF, Gazelle GS, Halpern EF, Goldberg SN. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology. 2003;226(2):441-451.
12. Dollinger M, Beyer LP, Haimerl M, et al. Adverse effects of irreversible electroporation of malignant liver tumors under CT fluoroscopic guidance: a single-center experience. Diagn Interv Radiol. 2015;21(6):471-475.
13. Cheung W, Kavnoudias H, Roberts S, Szakandra B, Kemp W, Thomson KR. Irreversible electroporation for unresectable hepatocellular carcinoma: initial experience and review of safety and outcomes. Technol Cancer Res Treat. 2013;12(3):233-241.
14. Livraghi T, Goldberg SN, Lazzaroni S, et al. Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions. Radiology. 2000;214(3):761-768.